For example, an expanded access study provided at-home administration of a PH FDC SC by a healthcare provider for patients with HER2+ breast cancer during the COVID-19 pandemic (NCT04395508), and a phase IIIb study is evaluating patient preference of PH FDC SC administration in a home vs. hospital setting during the crossover period of adjuvant treatment for early or locally advanced/inflammatory HER2+ breast cancer (NCT05415215, ProHer). This evidence concerns the gene ERBB2 and breast carcinoma.